Update shared on 18 Nov 2025
Fair value Decreased 2.85%Analysts have slightly lowered their price target for Eris Lifesciences from ₹1,860.10 to ₹1,807.10. They cite minor adjustments to growth projections and profitability estimates as the reason for this change.
What's in the News
- Board meeting scheduled for November 12, 2025, to consider and approve standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2025 (Company filing)
- The manufacturing unit at the Ahmedabad campus receives approval from Brazil's national health authority, ANVISA, following a successful inspection in May 2025. This approval paves the way for entry into the Brazilian pharmaceutical market (Company announcement)
Valuation Changes
- The consensus analyst price target has fallen slightly, from ₹1,860.10 to ₹1,807.10.
- The discount rate has increased marginally, moving from 12.73% to 12.76%.
- Revenue growth projections have decreased slightly, from 16.10% to 16.08%.
- The net profit margin estimate has edged down, from 23.00% to 22.99%.
- The future P/E ratio forecast has declined, from 34.30x to 33.05x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.